Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573861 | 0.91 | KDM4E (0.35) | KDM4EHKDC1MAPK1TACR1ALDH1A1 | |
| SCHEMBL12378088 | 0.91 | MAPK1 (0.32) | KDM4EHKDC1MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL14573860 | 0.86 | KDM4E (0.35) | KDM4EHKDC1MAPK1TACR1ALDH1A1 | |
| SCHEMBL12378094 | 0.85 | CYP2C19 (0.37) | KDM4EHTR6MAPK1TACR1ALDH1A1 | |
| SCHEMBL14573827 | 0.83 | KDM4E (0.35) | KDM4EHKDC1MAPK1TACR1ALDH1A1 | |
| SCHEMBL13943384 | 0.83 | KDM4E (0.41) | KDM4EHKDC1MAPK1TACR1ALDH1A1 | |
| SCHEMBL14270409 | 0.81 | KDM4E (0.40) | KDM4EHKDC1MAPK1TACR1ALDH1A1 | |
| SCHEMBL14294445 | 0.81 | KDM4E (0.38) | KDM4EHTR6HKDC1MAPK1TACR1 | |
| SCHEMBL4690940 | 0.77 | COMT (0.38) | KDM4EHKDC1MAPK1TACR1ALDH1A1 | |
| SCHEMBL14270415 | 0.77 | COMT (0.38) | KDM4EHKDC1MAPK1TACR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | KDM4E 1971/4885HTR6 3270/4885HKDC1 3846/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | KDM4E 960/4885HTR6 3850/4885HKDC1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.